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ABSTRACT                        Apoptotic cell death is an integral part of development and cell turnover in mul-
ticellular organisms. Since early 1970’s, when apoptosis was defined on morphological basis, 
plethora of genes has been identified participating in initiation, execution and regulation of 
cell death. This article reviews these latest advances and describes our present understanding 
of the sequential events of apoptotic cell death, from the early steps of death receptor initiated 
and mitochondrial pathways to activation of caspases, and finally, the proper corpse clearance. 
It also discusses dysregulation of apoptosis, leading to various pathologies, such as cancer, au-
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introduction
Multicellular organisms have evolved strictly regulated 
mechanisms for eliminating damaged, dangerous or surplus 
cells. This physiological form of cell death was originally 
described based on its characteristic cytological morphology 
and named apoptosis (Kerr et al. 1972), discriminating it from 
the accidental cell death, necrosis. As this process plays an 
essential role in normal embryonic development and adult 
tissue homeostasis and it is determined by genetic regulations, 
therefore it is also called programmed cell death. 
The morphological changes of the apoptotic cells manifest 
with pseudopodia retraction, detachment from the substrate, 
reduction of cellular and nuclear volume (pyknosis), nuclear 
fragmentation (karyorrhexis), blebbing of the plasma mem-
brane and package of the cell debris into apoptotic bodies 
(Kroemer et al. 2009), which are then engulfed by phagocytes 
in vivo. In contrast, necrotic cells undergo swelling of cyto-
plasmic organelles, including their nuclei, and the increase 
in their cell volume (oncosis) leads to rupture of the plasma 
membrane and loss of the intracellular material (Kroemer et 
al. 2009). Since the first description, it became clear that there 
are many “intermediate” forms of cell death between the clas-
sical apoptosis and necrosis, which can be more precisely dis-
tinguished based on molecular pathways. The new functional 
classification defines six main categories: extrinsic apoptosis, 
caspase-dependent intrinsic apoptosis, caspase-independent 
intrinsic apoptosis, regulated necrosis, autophagic cell death 
and mitotic catastrophe (Galluzzi et al. 2012). 
In this review we will focus on apoptotic pathways, trig-
gered either from outside of the cell by death ligands (ex-
trinsic or death receptor pathway) or from inside the cell as a 
response to various stress signals (intrinsic or mitochondrial 
pathway) (Fig. 1). In both pathways, signalling converges on 
the activation of cysteine proteases, named caspases, which 
burst a proteolytic cascade, leading to concerted destruction 
and elimination of the dying cell. 
Apoptosis induction by death receptors
The so-called “extrinsic apoptosis” is induced by extracel-
lular death ligands which crosslink specific transmembrane 
death receptors. Death ligands belong to the of the Tumour 
Necrosis Factor (TNF) superfamily, which includes CD95 
ligand/ Fas ligand (CD95L/FasL), tumour necrosis factor α 
(TNFα) and TNF-related apoptosis inducing ligand (TRAIL), 
expressed predominantly by immune cells (Guicciardi and 
Gores 2009). Accordingly, death receptors are members of 
the Tumour Necrosis Factor Receptor (TNFR) superfamily, 
transmitting decisive intracellular signals, leading to cell 
survival, activation, differentiation, inflammatory response 
or cell death (Guicciardi and Gores 2009). Only TNF recep-
tors with death domains (DD) recruit the signalling elements 
of the death pathway, namely the CD95/Fas, TNF-R1, DR3, 
TRAIL-R1, TRAIL-R2, DR6, EDAR and NGFR (Aggar-
wal 2003). These receptors are present on the cell surface 
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as trimers, through the interaction of the membrane-distal 
cysteine-rich domains of the extracellular part of the recep-
tors, a region termed the preligand assembly domain (PLAD, 
Chan et al. 2000). However, binding of the ligand is required 
for stabilizing the preassembled receptor and triggering the 
downstream processes.
Signalling by CD95 ligand/ Fas ligand and CD95/
Fas interaction
Binding of CD95 ligand/ Fas ligand (CD95L/FasL) to CD95/
Fas leads to conformational change, which promotes assem-
bly of a large protein complex, the Death Inducing Signaling 
Complex (DISC) (Fig. 1 and Fig. 2A) (Guicciardi and Gores 
2009). In DISC, adaptor proteins, procaspases and their in-
hibitors are recruited based on homotypic molecular interac-
tions between homologous domains. To the death domains 
(DD) present in the intracellular part of Fas, the adaptor 
protein FADD (Fas Associated Death Domain) is recruited 
by its homologous DD (Fig. 2A) (Chinnaiyan 1995). In ad-
dition, FADD contains another conserved domain, the Death 
Effector Domain (DED), which is found also in the large pro-
domain of procaspases-8 and -10 (Fig. 2A). Hence, DISC is a 
supramolecular complex where the initiator procaspases are 
recruited to, providing a platform for their dimerization and 
activation. However, inhibitors are recruited to this platform 
as well (Fig. 2A). The FLICE-like Inhibitory Protein (FLIP) 
has several isoforms that may regulate the dynamics of DISC 
Figure 1. The extrinsic and intrinsic pathways of apoptosis. The extrinsic pathway is triggered by death ligands, which bind to their specific 
death receptors in trimeric form. Ligation induces conformational change on the intracellular part, which then recruits adaptor proteins and 
initiator caspases, forming a large protein complex, named Death Inducing Signalling Complex (DISC). DISC is the platform for dimerization and 
activation of initiator procaspases-8 and -10. The intrinsic pathway is initiated by various cellular stresses, sensed by members of Bcl-2 family. 
Changes in the localization of Bcl-2 family proteins induce permeabilization of the mitochondrial outer membrane and release of cytochrome 
C. Cytochrome C facilitates assembly of apoptosome, where the initiator procaspase-9 is recruited and activated. Bid is cleaved by caspase-8 and, 
as a Bcl-2 family member, it promotes permeabilization of mitochondria, thereby providing a link between the extrinsic and intrinsic pathways 
and enhancing the apoptotic response. Initiator caspases trigger a proteolytic cascade of caspases, leading to activation of effector caspases, 
which are responsible for execution of cell death.
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composition and caspase activation (Safa 2012). cFLIP has 
similar structure as procaspase-8, therefore it is recruited to 
DISC by its DED domain, dimerizes with procaspase-8, but it 
has a mutant protease domain which inhibits the autocatalytic 
cleavage and activation of the protease. The outcome of the 
signalling pathway is largely dependent on the stoichiometry 
of the signalling elements present in DISC (Peter 2004). 
This basic structure is further complicated with additional 
signalling proteins, such as the receptor-interacting protein 
kinase 1 (RIP1) and the cellular inhibitor of apoptosis pro-
teins (cIAPs), which can shift the cellular response from 
apoptotic signal to survival and inflammation by activating 
NF-κB pathway (Wang et al. 1998). RIP1 is a DD-containing 
serine/threonine kinase, which binds to all death receptors 
and DD-containing adaptors (Meylan and Tschopp 2005). 
RIP is polyubiquitinated and thereby activated by cIAPs, 
which are E3 ubiquitin ligases, leading to phosphorylation 
and degradation of NF-κB inhibitory protein IκBα, allowing 
NF-κB to translocate to the nucleus and initiate transcription 
of anti-apoptotic target genes, such as cFLIP, cIAP-1, cIAP-2, 
TRAF1 and TRAF2 (Tumor Necrosis Factor Receptor Asso-
ciated Factor 1 and 2) (Wang et al. 1998), hence generating a 
positive feedback loop of pro-survival signalling.
Dichotomy of the TNF/TNFR signalling
In contrast to Fas, TNF-R1 is primarily involved in inflam-
matory immune response and not in apoptosis. Ligation of 
TNF-R1 triggers assembly of two subsequent signalling 
complexes (Guicciardi and Gores 2009). The first complex 
(complex I) consists of adaptor proteins TRADD (TNFR 
Associated Death Domain), RIP1, TRAF2 and/or TRAF5 
adaptor proteins and cIAP1/2 ubiquitin ligases, and results 
in activation of downstream NF-κB, JNK and p38 pathways. 
Figure 2. Mechanism of initiator caspase activation. A. Upon ligation by death ligands (i.e. CD95L/FasL), death domains (DD) in the intracellular 
tail of death receptors (i.e. CD95/Fas) recruit adaptor proteins with homologous DD, such as FADD (Fas Associated Death Domain). The other 
functional domains of these adaptors are the death effector domains (DED), which interact with DED prodomains of initiator procaspases -8 and 
-10. Recruitment of procaspases promotes their dimerization and autoproteolysis into large and small domains, thereby enhancing their activa-
tion. DED domains also recruit inhibitors like cFLIP (FLICE-like Inhibitory Protein), which hinders recruitment and dimerization of procaspases 
by sterical inhibition. B. Cytochrome C induces an opened conformation of Apaf-1 (Apoptotic protease-activating factor 1) and promotes its 
heptamerization in the presence of ATP, forming an apoptosome. The CARD domain of Apaf-1 recruits the CARD-domain containing initiator 
procaspase-9, and provokes its active conformation and cleavage. 
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The proteins upregulated by these transcription factors work 
against death signalling, and provide a regulatory mechanism 
to control cell death. Only when TNF-R1 is internalized after 
ligation, the pro-survival complex I dissociates, allowing 
FADD and procaspase-8 and -10 to form a cytosolic TNF-
R1-associated DISC (complex II) and initiate the downstream 
apoptotic processes (Guicciardi and Gores 2009). Endocytosis 
of TNF-R1 is decisive for assembly of complex II, and it is 
regulated by a cytoplasmic region named TNF-R1 internal-
ization domain (TRID) (Schneider-Brachert et al. 2004). The 
temporal and spatial distinction of complex I from complex 
II provides a checkpoint to control cell death, as the activa-
tion of initiator caspases may be diminished by the complex 
I-driven, NF-κB-dependent cFLIP expression. TNF-induced 
apoptosis is enhanced in the presence of protein synthesis 
inhibitors (cycloheximide), indicating the importance of the 
newly expressed anti-apoptotic proteins, and it is also pro-
moted by administration of cIAP inhibitors in vitro. Hence, 
the outcome of TNF-R1 ligation largely depends on the status 
of the cells, i.e. it can engage either the pro-survival NF-κB 
or the pro-death caspase signalling pathway.
Outcomes of TRAIL signalling
TRAIL/Apo2L triggers apoptosis by binding to one of its two 
cognate death receptors, TRAIL-R1 and TRAIL-R2 (Pan et 
al. 1997), expressed in most human tissues, including spleen, 
thymus, liver, peripheral blood leukocytes, activated T cells, 
small intestine, and some tumour cell lines. In addition, it has 
two decoy receptors, DcR1 and DcR, which lack functional 
intracellular death domains (Sheridan et al. 1997). Binding of 
TRAIL to decoy receptors fails to trigger apoptosis, moreover, 
it prevents TRAIL-induced apoptosis through TRAIL-R1 
and TRAIL-R2 by inhibiting the recruitment and activation 
of death signalling elements to DISC, and by shifting the 
cell response toward NF-κB activation (Degli-Esposti et al. 
1997). Apparently, most healthy cells are protected from 
TRAIL-triggered apoptosis by expressing decoy receptors, 
and TRAIL plays non-apoptotic functions in immunoregu-
lation. Expression of both TRAIL and its receptor on cells 
of the innate and adaptive immune systems is dependent on 
the stimulation status and it is modulated by viral and bacte-
rial infections. Results with TRAIL-/- and TRAIL-R-/- mice 
suggest that this ligand/receptor system has been primarily 
developed to fight infections and to control immune responses 
(Falschlehner et al. 2009).
Regulation of mitochondrial pathway by 
members of Bcl-2 family
The activation of the intrinsic death pathway is triggered 
by various stress signals that modify the cellular level and 
localization of Bcl-2 protein family members, controllers of 
the integrity of mitochondrial membrane. The imbalance in 
the anti-apoptotic and pro-apoptotic members of Bcl-2 protein 
family and the integration of pro-apoptotic ones into the outer 
membrane of mitochondria lead to release of cytochrome C 
(cyt C) from the mitochondrial intermembrane space, required 
for the subsequent formation of the apoptosome, a catalytic 
multiprotein platform for activation of caspase-9 (Fig. 1 and 
Fig. 2B) (Bender and Martinou 2013). Today, three function-
ally and structurally distinct subgroups of the Bcl-2 protein 
family are defined: 1. cell death initiating BH3-only proteins; 
2. the anti-apoptotic members such as the Bcl-2 itself; 3. the 
pro-apoptotic executioner proteins Bax and Bak (Bender and 
Martinou 2013). All family members share common Bcl-2 
homology domains (BH), however, the anti-apoptotic proteins 
and the pro-apoptotic Bax/Bak have four BH domains, while 
the BH3-only proteins have only one (Bender and Martinou 
2013).
The anti-apoptotic Bcl-2 proteins
The Bcl-2 (B-cell lymphoma 2) anti-apoptotic protein was 
identified in patients with pre-B-cell leukaemia and fol-
licular lymphoma carrying a chromosome translocation, 
which resulted in overexpression of an oncogenic protein 
(see below, Tsujimoto et al. 1985). Shortly, it turned out that 
Bcl-2 protected hematopoietic cells from cell death (Vaux et 
al. 1988) and that it was a functional homologue of CED-9, 
which prevented developmental cell death in C. elegans (Hen-
gartner and Horwitz 1994). To date, six human pro-survival 
family members have been identified: Bcl-2, Bcl-XL, Bcl-W, 
MCL-1, A1 and Bcl-B (Czabotar et al. 2014). These proteins 
have four BH domains and a transmembrane domain (TM) 
located near the carboxyl terminus which anchors them to 
intracellular membranes of mitochondria and other organ-
elles. It is suggested that the anti-apoptotic proteins bind and 
sequester the pro-apoptotic proteins, including the activator 
BH3-only proteins and Bax and Bak, to prevent apoptosis 
(Czabotar et al. 2014). 
The role of BH3-only proteins 
The BH3-only proteins are the sensors of stress signals and 
the molecular switch to apoptotic pathway (Fig. 3), as they 
interact with the multiregion pro-apoptotic and anti-apoptotic 
Bcl-2 family members, regulating their functions. There are at 
least 10 different BH3-only proteins in the vertebrate genome 
(Aouacheria et al. 2005) with different subcellular localization 
and cell type-specific expression, induced by many different 
types of cell stress. The specificity and affinity of the BH3-
only proteins for binding with their partners are determined 
by small differences in the amino acid sequence in the BH3 
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region. Only the so called “direct activators” – such as Bid, 
Bim, Puma – can directly bind to executioners, Bax and Bak. 
Other BH3 proteins (such as Bad, Bmf, Bik, Hrk, Noxa) are 
designated as “sensitizers”, as they have been shown to bind 
the anti-apoptotic Bcl-2 proteins, thereby blocking them from 
binding to the activator BH3 proteins and executioner pro-
teins (Häcker and Weber 2007). As BH3-only proteins play 
crucial role in initiating mitochondrial pathway of apoptosis, 
their activation is under strict regulation. BH3-only proteins 
are regulated by their cellular localization, posttranslational 
regulation - such as phosphorylation, myristoylation, ubiquit-
ination, proteolysis - or at transcriptional level. For example, 
Bim and Bmf are anchored to cytoskeleton in healthy cells 
(Puthalakath et al. 1999); Bad is sequestered by 14-3-3 when 
phosphorylated upon signalling from growth factors (Zha et 
al. 1996); Puma and Noxa are targets of p53 transcription 
factor (sensor of DNA damage – see below) (Nakano et al. 
2001; Oda et al. 2000); and Bid is cleaved by caspase-8 (Fig. 
1) providing an amplification loop for death ligand-induced 
pathway (Li et al. 1998).
According to the “embedded together” model, the sensi-
tizer BH3-only proteins bind the anti-apoptotic Bcl-2 proteins 
and liberate the activator BH3-only proteins and the execu-
tioner pro-apoptotic proteins, Bax and Bak (Fig. 3), allowing 
the activation and homo-oligomerization of the latter (Bender 
and Martinou 2013). 
The pro-apoptotic function of Bax and Bak
Bax and Bak are the multiregional Bcl-2 family members that 
form pores on the outer mitochondrial membrane, directly 
involved in releasing the pro-apoptotic factors from mito-
chondria (Bender and Martinou 2013). Both Bax and Bak 
are needed for maintaining normal development and tissue 
homeostasis, indicating that these proteins have overlapping 
functions (Lindsten et al. 2000). Bak resides in the outer 
mitochondrial membrane, but its oligomerization is inhibited 
by Bcl-XL in healthy cells (Griffiths et al. 1999). In contrast, 
Bax is predominantly a soluble protein in healthy cells cycling 
regularly to mitochondria, while its transmembrane domain is 
attached to its hydrophobic grove and unable to dock in mem-
branes (Wolter et al. 1997). Upon apoptotic trigger, binding of 
activator BH3-only proteins induces conformational change 
of Bax and it redistributes it to mitochondria (Griffiths et al. 
1999; Wolter et al. 1997), were it contributes to forming pores. 
The exact mechanism how Bax and Bak permeabilize the 
mitochondrial outer membrane is still under debate (Czabotar 
et al. 2014; Shamas-Din et al. 2013). During apoptosis, Bax 
and Bak change their structure and form homo-oligomers 
that can permeabilize the mitochondrial outer membrane. 
Recently, a second hydrophobic pocket of Bax was identi-
fied, termed the “rear pocket”, located on the opposite side 
from the canonical “front” BH3-binding pocket of Bax. It is 
suggested, that this pocket is masked when Bax is inactive 
and soluble in the cytoplasm, and it becomes exposed when 
Bax binds an activator BH3-only protein, triggering multiple 
conformational changes (Gavathiotis et al. 2010), leading to 
formation of pores, termed mitochondrial apoptosis-induced 
channel (MAC) (Pavlov et al. 2001). Current results show that 
Bax and Bak generate both proteinaceous and lipidic pores, 
large enough for releasing intermembrane space proteins, 
such as cytochrome C, OMI/HTRA2 and SMAC/DIABLO 
(Shamas-Din et al. 2013) (Fig. 3).
Figure 3. Members of Bcl-2 protein family regulate mitochondrial 
pathway. Various stress signals trigger changes in localization and 
expression of BH3-only proteins, which are the initiators of the mito-
chondrial apoptotic pathway. Sensitizer BH3-only proteins (BH3sen) 
bind to anti-apoptotic Bcl-2 proteins (i.e. Bcl-2 and Bcl-XL) and inhibit 
their guardian function. This releases the activator BH3-only proteins 
(BH3act) and the pro-apoptotic Bax and Bak from the inhibition of 
Bcl-2. BH3act proteins directly bind Bax and Bak and trigger their 
embedding to the outer membrane of mitochondria. Oligomers of 





Both the death receptor and mitochondrial pathways trigger 
activation of the caspase cascade (Fig. 1, Fig. 2A and B). 
Caspases are a family of endopeptidases, having catalytic 
cysteine residues in their active site and cleave after certain 
aspartic acids in the substrate bearing a consensus sequence 
(Riedl and Shi 2004). Fourteen mammalian caspases have 
been identified so far; however, they have different functions 
in regulating homeostasis, such as in differentiation, inflam-
mation or cell death. Apoptotic caspases are classified by their 
mechanism of action to group of initiators (caspases-2, -8, 
-10 and -9) and effectors (caspases-3, -6 and -7). Caspases-1, 
-4, -5 and -12 in humans and caspase-11 in mice have roles 
in inflammatory responses and discussed elsewhere (Riedl 
and Shi 2004). 
The caspase cascade
As caspases are the masters of cell degradation, their activi-
ties are regulated on multiple levels. Caspases are produced 
in inactive, zymogen form as procaspases, and require di-
merization and cleavage for activation (Riedl and Shi 2004) 
(Fig. 2). Dimerization of initiator caspases takes place on 
large molecular complexes assembled upon death receptor 
ligation or cyt C release from mitochondria. Procaspase-8 is 
recruited to DISC by its DED prodomain, and its dimeriza-
tion facilitates autocatalytic cleavage into large and small 
subunits resulting in stabilization of the dimer (Fig. 2A). 
This process has been described as an “induced proximity 
model” (Muzio et al. 1998). On the mitochondrial pathway, 
release and accumulation of cyt C in cytoplasm trigger con-
formational change of Apaf-1 (Apoptotic protease-activating 
factor 1) and, in the presence of cofactor dATP, they assemble 
to a large molecular complex, named apoptosome (Fig. 2B). 
Apaf-1 has three distinct domains: an N-terminal CARD for 
oligomerization; an expanded nucleotide-binding domain 
for dATP binding; and WD40 repeats for interaction with 
cyt C (Zou et al. 1997). Apoptosome has a wheel-like crystal 
structure, composed from seven units, with CARD domains 
in the middle, and WD40 on distal arms (Acehan et al. 2002). 
Homotypic interaction of CARD domains is also responsible 
for recruitment and activation of procaspase-9, which pos-
sesses a homologous CARD prodomain. In a recent study 
conducted with purified Apaf-1 and procaspase-9 CARD 
domains, an 11-mer complex was identified composed of 
seven molecules of Apaf-1 and four molecules of caspase-9, 
suggesting additional interfaces between these proteins (Hu 
et al. 2014). Surprisingly, procaspase-9 bound to the apopto-
some exhibits high catalytic activity even in the absence of 
the activation cleavage, which indicates allosteric regulation 
of its catalytic activity (Stennicke et al. 1999) and supports 
the induced conformation model. Once activated, the initiator 
caspases-8 and -9 can initiate a caspase cascade involving the 
downstream executioner caspases-3, -6 and -7 (Fig. 1). The 
effector caspases form dimers in their zymogen form, but 
require specific intrachain cleavage, leading to a conforma-
tional change in a critical loop in one caspase monomer to 
stabilize the active site loops in the adjacent monomer (Fig. 
4) (Riedl et al. 2001). 
Regulation of caspase activation
In addition to keeping caspases in zymogenic form until the 
apoptotic stimuli, various other mechanisms have been de-
scribed for regulation of caspase activity. As discussed above, 
inhibitory protein cFLIP and its isoforms block recruitment 
and dimerization of procaspase-8 in DISC. Activation of the 
pro-survival NF-κB signalling pathway enhances production 
of these inhibitory proteins and promotes expression of IAPs, 
too. IAPs are a conserved family of proteins, identified by 
bearing baculovirus IAP repeat domain (BIR) (Gyrd-Hansen 
and Meier 2010), which has a zinc-binding fold of approxi-
mately 70 amino acid residues that mediates protein–protein 
interactions (Hinds et al. 1999). The amino-terminal of 
mammalian IAPs, such as XIAP, cIAP1 and cIAP2 proteins 
contain three BIR domains, further classified to type I BIR 
and two type II BIR domains (Gyrd-Hansen and Meier 2010). 
Type II BIR domains have a deep peptide-binding groove 
for interaction with proteins carrying an IAP-binding motif 
(IBM), and have differential binding preferences for specific 
IBM-carrying proteins. The linker region preceding BIR2 
in XIAP binds to the IBMs of caspase-3 and caspase-7, in 
contrast, BIR3 binds to caspase-9, and their mechanism of 
inhibition is dissimilar (Gyrd-Hansen and Meier 2010). The 
BIR2 domain of XIAP binds to the neo-amino-terminus of 
effector caspases exposed following cleavage-mediated acti-
vation of caspase-3 and caspase-7 (Scott et al. 2005), while 
BIR3 binds to the homodimerization surface of caspase-9, 
interfering with dimerization-induced activation of this 
initiator caspase (Shiozaki et al. 2003). Mammalian IAPs 
also contain a carboxy-terminal RING domain indicating E3 
ubiquitin (Ub) ligase function and a Ub-associated (UBA) 
domain, and interfere with survival signalling pathways, such 
as NF-κB (see above). The caspase inhibition by IAPs can be 
overcome by their antagonists carrying IBM domains, such 
as the mitochondrial apoptotic factors, Smac/DIABLO and 
OMI/HTRA2, as they bind to the BIR domains and block their 
access to caspases (Vaux and Silke 2003), therefore enabling 
the caspases to execute their effective function.
Targets of caspases
Caspases’ substrate specificity is defined by 4-5 consensus 
amino acid sequence, with aspartic acid at the P1 primary 
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specificity position. This sequence is common for group of 
caspases, for example DEXD for effector caspases-3 and-7, 
and I/LEXD for initiator caspases-8 and -9 (D - Asp, E - Glu, 
I - Ile, L - Leu, X - any AA) (Poreba et al. 2013). This short 
sequence is present in several hundreds of proteins, putative 
caspase substrates, reported from modern, sensitive and high-
throughput proteomics studies (Crawford and Wells 2011). 
However, caspase cleavages are not all destructive, but as 
limited proteolysis they have different effects on different sub-
strates: they can cause loss, gain or change in target protein’s 
function or change in its localization (Crawford and Wells 
2011). Examples for gain-of-function cleavage are the activa-
tion of caspases themselves, but also the truncation of Bid, 
a BH3-only protein or the degradation of the inhibitor of the 
caspase-activated DNAse (CAD). The latter liberates CAD to 
catalyse fragmentation of nuclear DNA, which is considered 
as one of the hallmarks of apoptosis (Nagata 2000). Loss-
of-function cleavages degrade structural proteins (such as 
lamin, a nuclear structure protein), impair enzymes involved 
in energy-consuming synthesis processes that are no longer 
needed in a dying cell, and destroy activity of transcription 
factors participating in growth and differentiation programs 
(Crawford and Wells 2011). Cleavage by caspases can alter 
the subcellular localization of proteins by removing signal 
peptides. For example, Abl is a tyrosine kinase involved in 
cell survival signaling pathway in the cytoplasm, however, 
in response to DNA damage it concentrates in the nucleus 
and phosphorylates p53 and p73 transcription factors, which 
enhance expression of proapoptotic factors (see below). The 
shift of Abl toward nuclear localization is facilitated by the cut 
of its nuclear export signal (NES) by caspases-3, -7, thereby 
enhancing the apoptotic signalling (Barila et al. 2003).
Clearance of apoptotic cells
Apoptosis does not end with the structural degradation of the 
cells and fragmentation to small apoptotic bodies. Clearing of 
the apoptotic debris is at least as important as the triggering 
and signalling phases, since it protects from emerging of in-
flammatory and autoimmune responses (Hochreiter-Hufford 
and Ravichandran 2013). Without clearing, apoptotic bodies 
undergo secondary necrosis, i.e. rupture of the membrane 
and leakage of intracellular material, as it can be followed 
in the cell-cultures in vitro. In contrast, apoptotic bodies are 
rarely detected events in histological sections even in tissues 
with high cellular turnover, as they are rapidly engulfed by 
phagocytes in vivo. This can be performed by any cell type, 
which is capable of engulfment, including “professional” 
phagocytes, such as macrophages and immature dendritic 
cells, and the neighboring “nonprofessional” phagocytes 
in all tissues (Hochreiter-Hufford and Ravichandran 2013). 
Clearance has a regulated choreography: first, apoptotic cells 
release so called “find me” signals, which are chemotactic 
factors for phagocytes. Dying cells also express “eat-me” 
signals, which provide contact with and recognition by the 
phagocytes, triggering signals for the engulfment process. 
Finally, endocytosis of apoptotic bodies upregulates produc-
tion of anti-inflammatory cytokines, keeping the clearance 
events “immunologically silent” (Hochreiter-Hufford and 
Ravichandran 2013) (Fig 5).
Recruitment of phagocytes
The “find-me” signals establish a chemotactic gradient 
Figure 4. Mechanism of effector caspase activation. Effector caspases form dimers in their zymogen form, but they are not active unless cleaved 
by initiator caspases. Cut in the loop between the large and small domains induces conformational change in the active site of the dimerization 
partner, stabilizing it and enhancing its enzymatic activity.
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stimulating migration of phagocytes to the apoptotic cell. 
The most intensively examined “find-me” factors are the 
lysophosphatidylcholine (LPC), sphingosine-1-phosphate 
(S1P), fractalkine (CXC3CL1 chemokine) and the nucle-
otides ATP and UTP, however, their exact action is yet under 
debate (Hochreiter-Hufford and Ravichandran 2013). LPC 
was the first “find-me” signal described. It is a product of the 
caspase-3-dependent activation of phospholipase A2, which 
converts the membrane phosphatidylcholine to LPC (Lauber 
et al. 2003). However, the concentration of LPC reported to 
be required for macrophage chemotaxis appears to be quite 
high, making LPC an unlikely candidate for a chemotactic 
mediator. It also acts as an “eat-me” signal, being a surface-
bound target for IgM. The other lipid mediator, S1P is pro-
duced by sphingosine kinase 1 (SphK1) (Gude et al. 2008), 
and stimulates chemotaxis, although it also seems to have 
additional function by enhancing the immunosuppressive 
factors, IL-10 and PGE2 by macrophages. Fractalkine is a 
membrane-associated protein released by B-lymphocytes 
and neurons, and it is sensed by the macrophage chemokine 
receptor, CX3CR1, hence it is suggested to be a chemotactic 
factor, however, its production is not uniform in every cell 
type. (Truman et al. 2008). Recently, nucleotides ATP and 
UTP have been proposed as a new class of “find me” sig-
nals. These are released is small amounts via the pannexin 
channels, opened as a result of cleavage by caspases, and 
they establish a short-range chemotactic gradient for tissue 
resident macrophages that express the nucleotide-sensitive 
P2Y2 receptor (Elliott et al. 2009).
Recognition of apoptotic cells and provoking 
engulfment
The molecular composition of the plasma membrane of an 
Figure 5. Phases of clearing of apoptotic cells. I. Dying cells release “find me” signals, which provide chemotactic gradient for recruitment of 
phagocytes. II. Changes in the surface pattern of apoptotic cells offer “eat me” signals, recognized by scavenger receptors of phagocytes. III. 
Activation signals triggered from scavenger receptors lead to cytoskeletal rearrangements and engulfment of apoptotic corpse. IV. Processing 
of endocytosed apoptotic debris promotes release of anti-inflammatory cytokines.
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apoptotic cell differs from healthy cells in displaying “eat 
me” signals, which are detected by phagocytes either di-
rectly with their scavenger receptors or with help of bridging 
molecules. In addition, living cells express “don’t eat me” 
signals on their surface, like CD47 (also known as integrin-
associated protein) and CD31, which inhibit engulfment by 
phagocytes (Oldenborg et al. 2000; Brown et al. 2002). In 
case of apoptotic cells, changes in glycosylation of surface 
proteins and in surface charge and expression of oxidized low-
density lipoprotein (LDL)-like moiety provokes recognition 
by phagocytes directly or through binding of serum proteins 
such as thrombospondin and complement C1q (Ravichandran 
and Lorenz 2007). The most widely known “eat me” signal 
is the phospholipid phosphatidylserine (PtdSer) (Fadok et 
al. 1992), which is immersed in the inner leaflet of the lipid 
bilayer in viable cells, but it rapidly translocates to the outer 
leaflet in apoptotic cells by a caspase-dependent mechanism. 
Certain intracellular proteins such as calreticulin and annexin 
I, are also exposed and function as bridging molecules by 
binding to and enhancing the recognition of PtdSer (Arur 
et al. 2003; Gardai et al. 2005). Receptors expressed on the 
surface of phagocytic cells that recognize “eat me” signals 
include lectins that bind altered sugars on apoptotic cells, 
CD36 (in conjunction with integrins αvβ3 and αvβ5) that 
binds thrombospondin, LRP1/CD91 (in conjunction with 
calreticulin) that binds complement C1q, and the scavenger 
receptors that bind oxidized LDL (Hochreiter-Hufford and 
Ravichandran 2013). In addition, secreted proteins such as 
MFG-E8, growth-arrest-specific 6 (Gas6), and protein S have 
also been shown to bind PtdSer, and as bridging molecules 
they promote engulfment via their cognate receptors such as 
the Tyro-3-Axl-Mer family of receptors (TAM receptors) on 
phagocytes (Nakano et al. 1997). 
Upon recognition of the apoptotic cell, the phagocyte 
undergoes cytoskeletal rearrangements necessary for corpse 
engulfment. Most phagocytic receptors are connected with 
the CrkII–Dock180–ELMO signalling pathway, having 
evolutionary conserved function in clearance. Dock180 is 
a specific guanine-nucleotide- exchange factor (GEF), re-
sponsible for activation of Rho family GTPases, such as Rac, 
which in turn promote actin polymerization and cytoskeletal 
rearrangement. Recognition and engulfment of apoptotic cells 
trigger secretion of anti-inflammatory cytokines (TGF-β and 
IL-10) from the phagocyte, which induce differentiation of 
regulatory T-cells and T helper 2 cells, thereby dampening 
or resolving inflammation (Green et al. 2009). In addition, 
degradation and processing of apoptotic cell material by 
professional phagocytes, such as dendritic cells, establish 
and maintain tolerance by modulating self-antigen presenta-
tion. Defects at any points of clearance (lack of phagocytic 
receptors, improper degradation after engulfment) may lead 
to development of wide variety of human pathologies, for 
example autoimmune diseases (systemic lupus erythemato-
sus and rheumatoid arthritis), pulmonary diseases (chronic 
obstructive pulmonary disease and asthma), cardiovascular 
diseases (atherosclerosis), neurological diseases (Alzheimer’s 
disease) and cancer (Elliott and Ravichandran 2010).
Malfunctioning of apoptosis
As apoptosis is a basic biological process in the maintenance 
of tissue homeostasis, alterations in apoptotic pathway can 
lead to various diseases. Both the reduced and increased 
apoptotic processes can be involved in the pathomechanism of 
cancer, several types of autoimmune diseases, neurodegenera-
tive diseases and cardiovascular diseases (Table 1). 
Defective apoptosis in cancer
Failure of apoptosis allows survival of transformed cells, 
which are prone to undergo further genetic damage. Suppres-
sion of apoptosis plays a central role in tumour progression 
and it may be responsible for resistance to cancer therapy as 
well (Lowe and Lin 2001). Cancer cells can decrease apop-
tosis via mutations in key regulatory genes, downregulation 
of expression of proapoptotic molecules or overexpression of 
apoptosis inhibitors as well. Surprisingly, the frequency of so-
matic mutations in caspase genes is relatively low in tumours. 
In genes of initiator caspases, i.e. caspase-8 and -10 the muta-
tion rate is around 10% in various cancer types, however, it is 
only 2% in genes of effector caspases, like caspase-3, -6, and 
-7, represented only in a few tumour types (McIlwain et al. 
2013). Genetic studies have shown that inactivation of indi-
vidual caspases is usually not sufficient to block the caspase 
cascade. Instead, malignant cells more frequently inactivate 
the upstream mediators of caspase activation. 
Table 1. Defective apoptosis leads to pathological disorders.





Lung Amyotrophic lateral sclerosis
Neuroblastoma Neurodegeneration after stroke
Autoimmune disorders: Cardiovascular diseases:
Systemic lupus erythematosus Myocardial infarction
Myasthenia gravis
Other disorders Other disorders






In contrary to caspase genes, the master regulator of 
apoptosis, TP53 tumour-suppressor gene is mutated in more 
than 50% of all tumour types (Wallace-Brodeur and Lowe 
1999). These somatic mutations arise spontaneously or as 
a consequence of DNA damage in tumour cells. Mutations 
are usually missense, single base mutations in DNA-binding 
domain of TP53, which lead to loss of function of p53 pro-
tein (Whibley et al. 2009). In normal cells, p53 activates 
the intrinsic apoptotic pathway through transactivation or 
transcription-independent mechanism. In nucleus, p53 induce 
gene expression of several members of BH3-only protein fam-
ily (Puma, Noxa and Hrk) as a transcription factor, while at 
mitochondria it interacts directly with members of the Bcl-2 
family that leads to cytochrome C release and caspase-9 ac-
tivation (Amaral et al. 2010). p53 also activates the extrinsic 
apoptotic pathway through the induction of genes encoding 
Fas, DR5 and Bid, the latter linking the extrinsic and intrinsic 
apoptotic pathways. Furthermore, p53 is involved in the acti-
vation of the apoptosome via induction of Apaf-1 expression 
(Amaral et al. 2010). The central role of p53 in tumourigen-
esis is indicated by germline TP53 mutations. Individuals with 
Li-Fraumeni syndrome harbouring germline TP53 mutations 
have an increased risk of developing various tumour types like 
sarcomas, breast cancers or brain tumours at an early age of 
onset. Similar to somatic mutations, germline Li-Fraumeni 
mutations are most often missense base substitutions in DNA-
binding domain of TP53 (Malkin 1993). 
While mutations in p53 lead to loss of normal functions in 
apoptosis regulation, the another significant regulator, Bcl-2 
displays a gain of function phenotype. Bcl-2 is upregulated 
in a variety of tumour types resulting in imbalance between 
the anti-apoptotic Bcl-2 and pro-apoptotic Bax, subsequently 
leading to decreased intrinsic apoptotic pathway in cells. In 
most cases of B-cell lymphomas, the elevated level of Bcl-2 
is a result of translocation between chromosome 14q32 region 
and chromosome 18q21 region, bringing the BCL-2 gene un-
der the control of the immunoglobulin heavy-chain enhancer 
(Tsujimoto et al. 1985), hence giving eternal life for B-cells. 
Additional mechanisms for increased Bcl-2 expression oc-
cur in about 50% of all human cancers. Among these are the 
loss of endogenous microRNAs (miRs) that normally repress 
BCL-2 gene expression and altered epigenetic regulation due 
to gene hypomethylation (Yip and Reed 2008). In addition 
to involvement in tumourigenesis, decreased apoptosis may 
be responsible for drug resistance in cancer chemotherapy as 
well. Currently several compounds regulating apoptosis enter 
clinical trials to evaluate their efficacy in cancer treatment 
(Fischer et al. 2005).
TRAIL-receptor has been suggested to play role as a 
metastasis suppressor in multiple tissues based on the in 
vivo studies with TRAILR-deficient mice (Grosse-Wilde 
et al. 2008), which gives hope for TRAIL-based therapy in 
human cancer. However, the translation of TRAIL into the 
clinic turned to be aggravated by its short half-life, lacking of 
adequate delivery methods, and presence of TRAIL-resistant 
cancer cell populations (Stuckey and Shah 2013). Use of 
TRAIL-receptor targeting monoclonal antibodies has been 
successful in preclinical studies and entered clinical trials. 
The phase I trials of soluble recombinant TRAIL or TRAIL-R 
monoclonal antibodies have been undertaken on patients with 
advanced solid tumours, and these compounds were largely 
well tolerated, nevertheless, their anticancer response was 
poor, showing no remission. Currently, combination therapies 
are in ongoing trials, and their relative success remains to be 
evaluated (Stuckey and Shah 2013).
Problems with apoptosis in the nervous system
Programmed cell death is part of the normal nervous system 
development, but excessive apoptosis in adults plays role in 
the pathomechanism of several neurodegenerative diseases. 
Contrary to most of somatic cells, neurons do not repli-
cate and they live for a long time, therefore, elevated level 
of apoptosis in certain neurons results in diminished cell 
number in a particular region of adult brain. For example, 
progressive loss of motoneurons manifests as Amyotrophic 
Lateral Sclerosis (ALS), characterized by muscle atrophy and 
paralysis; apoptosis of cortical and hippocampal neurons is 
responsible for the symptoms of Alzheimer’s disease (AD) 
which is an irreversible, progressive dementia; Huntington’s 
chorea (HD) involves death of neurons in the striatum that 
control body movements, resulting in abnormal involuntary 
movement; specific loss of dopaminerg midbrain neurons 
underlies Parkinson’s disease (PD) characterized by lesions 
in the substantia nigra (Hee and Keun 2013). Elevated caspase 
activity is a common feature of neurodegenerative disorders. 
Caspase-1, -3 and -9 activities are higher in ALS patients 
than in controls (Hee and Keun 2013) and apoptosis in the 
motor neurons may contribute to the disease, although the 
molecular pathomechanism of ALS is not clear. The main 
feature in AD is amyloid β-peptide (APP) aggregation in 
extracellular deposits, causing neurotoxic plaques. Here, 
caspase-3 is indicated as the main caspase involved in mutant 
amyloid precursor protein cleavage (Gervais et al. 1999), 
and the resulting APP is considered to induce apoptosis by 
causing oxidative stress in neurons and glia. Moreover, the 
N-terminal APP fragment activates the extrinsic apoptotic 
pathway which leads to caspase-6 dependent axonal degen-
eration (Nikolaev et al. 2009). The exact mechanism of cell 
death in HD is unclear yet, but it is possible that peptide frag-
ments of mutant huntingtin protein generated by caspase-6 
cause the neuropathological symptoms (Graham et al. 2010). 
In PD animal models, involvement of caspase-1 and -3 in cell 
death has been proved, in addition, PTEN-induced kinase-1 
(PINK-1) mutation results in elevated levels of capase-3 and 
-9 activation (Wood‐Kaczmar et al. 2008). Better understand-
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ing of the molecular mechanisms of neuronal apoptosis may 
promote introduction of anti-apoptotic drugs in therapy of 
neurodegenerative disorders in future. 
Conclusive remarks
Our understanding of the regulation of apoptosis and its role 
in tissue dynamics of multicellular organisms has greatly 
expanded in recent years. Identification of protein families 
involved in execution and regulation of apoptosis boosted 
the studies defining their exact place and role in apoptotic 
signalling machinery. However, many questions regarding 
the structure of these proteins after conformational change, 
oligomerization and membrane anchorage, are still open. 
Uncovering the delicate interrelationship between the players 
of apoptosis gives tools to fight diseases with abnormal cell 
destruction or excessive cell survival.
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